Results 121 to 130 of about 684,663 (243)

m6A‐Mediated Glycolysis by IL‐37 Drives T Cell Metabolic Reprogramming to Regulate Colitis

Advanced Science, EarlyView.
This study identifies an IL‐37/SIGIRR‐METTL14 regulatory axis that suppresses global m6A modification in CD4+ T cells. IL‐37 signaling, mediated through SIGIRR, inhibits IRAK4 and JNK phosphorylation, leading to downregulation of the methyltransferase METTL14.
Xiaoyan Wang, Jiadong Yu, Guolin Li, Ya Li, Fanlian Zeng, Jing Hu, Yifan Zhou, Chengcheng Yue, Qixiang Zhao, Chen Zhang, Hong Zhou, Fulei Zhao, Yawen Hu, Pei Zhou, Linna Gu, Yuting Feng, Mingxiang He, Shishi Huang, Xiaochi Sun, Xinmeng Wang, Jie Tang, Xinyu Zeng, Wenling Wu, Nongyu Huang, Xinai Cui, Kaijun Cui, Jiong Li   +26 more
wiley   +1 more source

GABA/baclofen stabilizes PD-L1 and enhances immunotherapy of breast cancer

Heliyon
The programmed death-ligand 1 (PD-L1) on the surface of tumor cells binds to the receptor programmed cell death protein 1 (PD-1) on effector T cells, thereby inhibiting the anti-tumor immune response. Immune checkpoint blockade (ICB) therapy targeting PD-
Xue Sun, Mingen Lin, Ziyin Tian, Yan Ma, Lei Lv   +4 more
doaj   +1 more source

Full‐Body AI Agent: A Perspective on Multi‐Scale Collaborative AI for Systemic Biology and Precision Medicine

Advanced Science, EarlyView.
We propose the Full‐Body AI Agent, a multi‐scale collaborative framework with 7 biological‐layer agents. It unifies multi‐omics/clinical data via standardized protocols, enabling phenotype‐guided closed‐loop reasoning, quantitative evaluation, and LLM safeguards, with promising applications in tumor metastasis modeling and precision drug development ...
Aoqi Wang, Jiajia Liu, Jianguo Wen, Yangyang Luo, Zhiwei Fan, Liren Yang, Xi Hu, Ruihan Luo, Yankai Yu, Sophia Li, Weiling Zhao, Xiaobo Zhou   +11 more
wiley   +1 more source

Bioprinted Tumor Microenvironment Models Reveal Immune Evasion and Guide CAR‐NK Therapeutic Strategies

Advanced Science, EarlyView.
This study presents a 3D embedded bioprinting platform that recapitulates key stromal features of the tumor microenvironment using fibroblasts and lung‐derived ECM. The model enables functional assessment of CAR‐NK cells and provides a versatile tool to support the development of next‐generation immunotherapeutic strategies against solid tumors ...
Dahong Kim, Seona Jo, In‐Hwan Jang, Yu‐Jin Kim, Youngmee Jung, Junhyoung Ahn, Hyungjun Lim, Jae Jong Lee, Kangwon Lee, Tae‐Don Kim, Su A Park   +10 more
wiley   +1 more source

Overview of PD-L1 expression by different anti-PD-L1 clones across the different subtypes of lymphomas.

, 2016
Overview of PD-L1 expression by different anti-PD-L1 clones across the different subtypes of lymphomas.
Jeffery Kimbrough (3353009), Ryan Bender (3353018), Aida Dizdarevic (3353006), Nurija Bilalovic (3353015), Nilanjan Ghosh (2032558), David Arguello (3353000), Semir Vranic (3353012), Zoran Gatalica (3353003), Yvonne Veloso (3353021)   +8 more
core   +1 more source

Cancer‐Associated Fibroblasts Promote Tumor Immunosuppression in Hepatocellular Carcinoma via the NNMT‐ANGPTL4 Axis

Advanced Science, EarlyView.
ABSTRACT Background & Aims: Cancer‐associated fibroblasts (CAFs) drive immunosuppression in hepatocellular carcinoma (HCC). However, their metabolic regulation remains poorly defined. We investigated the role of nicotinamide N‐methyltransferase (NNMT) in CAFs. Approach & Results: High NNMT expression in CAF tissues was confirmed by western blotting and
Shounan Lu, Shanjia Ke, Hongjun Yu, Zhanzhi Meng, Miaoyu Bai, Yanan Xu, Hui Zhu, Jinwen Yang, Baolin Qian, Bing Yin, Chaoqun Wang, Zhigang Feng, Zhongyu Li, Yongzhi Zhou, Zihao Li, Xinglong Li, Yongliang Hua, Yao Fu, Wei Tang, Yaohua Wu, Yong Ma   +20 more
wiley   +1 more source

High tumoral PD-L1 expression and low PD-1+ or CD8+ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system

OncoImmunology, 2019
We investigated the clinicopathological role of the PD-1/PD-L1 pathway in primary diffuse large B-cell lymphoma of the central nervous system (PCNS-DLBCL) arising in the immune-privileged site.
Sehui Kim, Soo Jeong Nam, Changhee Park, Dohee Kwon, Jeemin Yim, Seung Geun Song, Chan-Young Ock, Young A Kim, Sung Hye Park, Tae Min Kim, Yoon Kyung Jeon   +10 more
doaj   +1 more source

272 PD-L1 CAR engineered K-NK cells to target PD-L1⁺ or PD-L1^- tumors

Regular and Young Investigator Award Abstracts, 2023
Pedro Romero, Andre Kunert, Hardikkumar Jetani, Katarzyna Franciszkiewicz, David Vlerick, Aleksandra Nowicka, Robert Y Igarashi   +6 more
openaire   +2 more sources

PD-L1 Status in Refractory Lymphomas - Fig 2

, 2016
(A): Hematoxylin and Eosin (H&E) slide of a case of lymphocyte depleted variant of classical Hodgkin lymphoma (cHL); (B): The tumor cells were diffusely (100%) and strongly (3+) positive for PD-L1 protein by immunohistochemistry (clone: SP142); (C-D ...
Jeffery Kimbrough (3353009), Ryan Bender (3353018), Aida Dizdarevic (3353006), Nurija Bilalovic (3353015), Nilanjan Ghosh (2032558), David Arguello (3353000), Semir Vranic (3353012), Zoran Gatalica (3353003), Yvonne Veloso (3353021)   +8 more
core   +1 more source

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade

Advanced Science, EarlyView.
This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to
Teng Zhou, Yifei Zhu, Cheng Zeng, Jinlu Han, Huiying Huang, Doudou Li, Mingxi Lin, Yizi Jin, Qin Guo, Yuxin Yan, Xinhui Mao, Yifei Zhou, Jian Zhang   +12 more
wiley   +1 more source